Triptolide induces apoptosis and inhibits the growth and angiogenesis of human pancreatic cancer cells by downregulating COX-2 and VEGF

Oncology Research

Volumn 20, Issue 8, 2013, Pages 359-368

  Ma, Jian Xia ^a   Sun, Yun Liang ^b   Wang, Yi Qian ^a   Wu, Hong Yu ^c   Jin, Jing ^c   Yu, Xiao Feng ^a  

^a FUDAN UNIVERSITY   (China)

^b People's Hospital of Ganyu County   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Cyclooxygenase 2 (COX 2); Pancreatic cancer; Triptolide (TPL); Vascular endothelial growth factor (VEGF)

Indexed keywords

CYCLOOXYGENASE 2; MATRIGEL; TRIPTOLIDE; VASCULOTROPIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; NICK END LABELING; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING;

EID: 84879670401     PISSN: 09650407     EISSN: 15553906     Source Type: Journal    
DOI: 10.3727/096504013X13657689382932     Document Type: Article

References (37)

1. Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics 2012. CA. Cancer. J. Clin. 62:10-29; 2012.
2. Lockhart, A. C.; Rothenberg, M. L.; Berlin, J. D. Treatment for pancreatic cancer: Current therapy and continued progress. Gastroenterology 128:1642-1654; 2005.
3. Li, D.; Xie, K.; Wolff, R.; Abbruzzese, J. L. Pancreatic cancer. Lancet 363:1049-1057; 2004.
4. Maitra, A.; Hruban, R. H. Pancreatic cancer. Annu. Rev. Pathol. 3:157-188; 2008.
5. Corson, T. W.; Crews, C. M. Molecular understanding and modern application of traditional medicines: Triumphs and trials. Cell 130:769-774; 2007.
6. Chen, B. J. Triptolide, a novel immunosuppressive and anti-inflammatory agent purified from a Chinese herb Tripterygium wilfordii Hook f. Leuk. Lymphoma 42:253-265; 2001.
7. Qiu, D.; Kao, P. N. Immunosuppressive and anti-inflammatory mechanisms of triptolide, the principal active diterpenoid from the Chinese medicinal herb Tripterygium wilfordii Hook f. Drugs R D 4:1-18; 2003.
8. Chang, W. T.; Kang, J. J.; Lee, K. Y.; Wei, K.; Anderson, E.; Gotmare, S.; Ross, J. A.; Rosen, G. D. Triptolide and chemotherapy cooperate in tumor cell apoptosis. A role for the p53 pathway. J. Biol. Chem. 276:2221-2227; 2001.
9. Yang, S.; Chen, J.; Guo, Z.; Xu, X. M.; Wang, L.; Pei, X. F.; Yang, J.; Underhill, C. B.; Zhang, L. Triptolide inhibits the growth and metastasis of solid tumors. Mol. Cancer Ther. 2:65-72; 2003.
10. Zhou, G. X.; Ding, X. L.; Huang, J. F.; Zhang, H.; Wu, S. B. Suppression of 5-lipoxygenase gene is involved in triptolide-induced apoptosis in pancreatic tumor cell lines. Biochim. Biophys. Acta 1770:1021-1027; 2007.
11. Johnson, S. M.; Wang, X.; Evers, B. M. Triptolide inhibits proliferation and migration of colon cancer cells by inhibition of cell cycle regulators and cytokine receptors. J. Surg. Res. 168:197-205; 2011.
12. Okami, J.; Yamamoto, H.; Fujiwara, Y.; Tsujie, M.; Kondo, M.; Noura, S.; Oshima, S.; Nagano, H.; Dono, K.; Umeshita, K.; Ishikawa, O.; Sakon, M.; Matsuura, N.; Nakamori, S.; Monden, M. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin. Cancer Res. 5:2018-2024; 1999.
13. Petkova, D. K.; Clelland, C.; Ronan, J.; Pang, L.; Coulson, J. M.; Lewis, S.; Knox, A. J. Overexpression of cyclooxygenase-2 in non-small cell lung cancer. Respir. Med. 98:164-172; 2004.
14. Wang, D.; Dubois, R. N. Cyclooxygenase-2: A potential target in breast cancer. Semin. Oncol. 31:64-73; 2004.
15. Kato, H.; Yoshikawa, M.; Miyazaki, T.; Nakajima, M.; Fukai, Y.; Masuda, N.; Fukuchi, M.; Manda, R.; Tsukada, K.; Kuwano, H. Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) in esophageal squamous cell carcinoma. Anticancer Res. 22:3977-3984; 2002.
16. Saad, R. S.; El-Gohary, Y.; Memari, E.; Liu, Y. L.; Silverman, J. F. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma. Hum. Pathol. 36:955-961; 2005.
17. Patard, J. J.; Rioux-Leclercq, N.; Masson, D.; Zerrouki, S.; Jouan, F.; Collet, N.; Dubourg, C.; Lobel, B.; Denis, M.; Fergelot, P. Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma. Br. J. Cancer 101:1417-1424; 2009.
18. Wu, Y.; Jin, M.; Xu, H.; Shimin, Z.; He, S.; Wang, L.; Zhang, Y. Clinicopathologic significance of HIF-1α, CXCR4, and VEGF expression in colon cancer. Clin. Dev. Immunol. pii: 537531; 2010.
19. Gately, S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev. 19:19-27; 2000.
20. Livak, K. J.; Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2[-Delta Delta C(T)] method. Methods 25:402-408; 2001.
21. Giannopoulos, G.; Pavlakis, K.; Parasi, A.; Kavatzas, N.; Tiniakos, D.; Karakosta, A.; Tzanakis, N.; Peros, G. The expression of matrix metalloproteinases-2 and -9 and their tissue inhibitor two in pancreatic ductal and ampullary carcinoma and their relation to angiogenesis and clinicopathological parameters. Anticancer Res. 28:1875-1881; 2008.
22. Wang, W.; Li, X.; Sun, W.; Zhang, L.; Zhang, M.; Hong, B.; Lv, G. Triptolide triggers the apoptosis of pancreatic cancer cells via the downregulation of Decoy receptor 3 expression. J. Cancer Res. Clin. Oncol. 138:1597-605; 2012.
23. Li, H.; Takai, N.; Yuge, A.; Furukawa, Y.; Tsuno, A.; Tsukamoto, Y.; Kong, S.; Moriyama, M.; Narahara, H. Novel target genes responsive to the antigrowth activity of triptolide in endometrial and ovarian cancer cells. Cancer Lett. 297:198-206; 2010.
24. Li, W.; Liu, Y.; Li, X. X.; Yu, Y.; Wu, J. J.; Wang, Q.; Huo, H.; Wang, L. M.; Yang, L. MAPKs are not involved in triptolide-induced cell growth inhibition and apoptosis in prostate cancer cell lines with different p53 status. Planta Med. 77:27-31; 2011.
25. Kim, M. J.; Lee, T. H.; Kim, S. H.; Choi, Y. J.; Heo, J.; Kim, Y. H. Triptolide inactivates Akt and induces caspase-dependent death in cervical cancer cells via the mitochondrial pathway. Int. J. Oncol. 37:1177-1185; 2010.
26. Tan, B. J.; Tan, B. H.; Chiu, G. N. Effect of triptolide on focal adhesion kinase and survival in MCF-7 breast cancer cells. Oncol. Rep. 26:1315-1321; 2011.
27. Carter, B. Z.; Mak, D. H.; Shi, Y.; Fidler, J. M.; Chen, R.; Ling, X.; Plunkett, W.; Andreeff, M. MRx102, a triptolide derivative, has potent antileukemic activity in vitro and in a murine model of AML. Leukemia 26:443-450; 2012.
28. Luo, Y.; Shi, C.; Liao, M. Advance in the antitumor mechanism of triptolide. Zhongguo. Zhong Yao Za Zhi 34:2024-2026; 2009.
29. Phillips, P. A.; Dudeja, V.; McCarroll, J. A.; Borja-Cacho, D.; Dawra, R. K.; Grizzle, W. E.; Vickers, S. M.; Saluja, A. K. Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70. Cancer Res. 67:9407-9416; 2007.
30. Antonoff, M. B.; Chugh, R.; Borja-Cacho, D.; Dudeja, V.; Clawson, K. A.; Skube, S. J.; Sorenson, B. S.; Saltzman, D. A.; Vickers, S. M.; Saluja, A. K. Triptolide therapy for neuroblastoma decreases cell viability in vitro and inhibits tumor growth in vivo. Surgery 146:282-290; 2009.
31. Ding, X.; Zhou, X.; Zhang, H.; Qing, J.; Qiang, H.; Zhou, G. Triptolide augments the effects of 5-lipoxygenase RNA interference in suppressing pancreatic tumor growth in a xenograft mouse model. Cancer Chemother. Pharmacol. 69:253-261; 2012.
32. Subbaramaiah, K.; Dannenberg, A. J. Cyclooxygenase 2: A molecular target for cancer prevention and treatment. Trends Pharmacol. Sci. 24:96-102; 2003.
33. Cerella, C.; Sobolewski, C.; Dicato, M.; Diederich, M. Targeting COX-2 expression by natural compounds: A promising alternative strategy to synthetic COX-2 inhibitors for cancer chemoprevention and therapy. Biochem. Pharmacol. 80:1801-1815; 2010.
34. Korpanty, G.; Smyth, E.; Sullivan, L. A.; Brekken, R. A.; Carney, D. N. Antiangiogenic therapy in lung cancer: Focus on vascular endothelial growth factor pathway. Exp. Biol. Med. (Maywood). 235:3-9; 2010.
35. Zhu, W.; He, S.; Li, Y.; Qiu, P.; Shu, M.; Ou, Y.; Zhou, Y.; Leng, T.; Xie, J.; Zheng, X.; Xu, D.; Su, X.; Yan, G. Antiangiogenic activity of triptolide in anaplastic thyroid carcinoma is mediated by targeting vascular endothelial and tumor cells. Vascul. Pharmacol. 52:46-54; 2010.
36. Li, C. J.; Chu, C. Y.; Huang, L. H.; Wang, M. H.; Sheu, L. F.; Yeh, J. I.; Hsu, H. Y. Synergistic anticancer activity of triptolide combined with cisplatin enhances apoptosis in gastric cancer in vitro and in vivo. Cancer Lett. 319:203-213; 2012.
37. Tang, X. Y.; Zhu, Y. Q.; Tao, W. H.; Wei, B.; Lin, X. L. Synergistic effect of triptolide combined with 5-fluorouracil on colon carcinoma. Postgrad. Med. J. 83:338-343; 2007.